Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to determine the safety and Maximum tolerated dose
(MTD) of BIBF 1120 combination therapy with docetaxel and prednisone in patients with hormone
refractory prostate cancer. Secondary objectives were to characterise the pharmacokinetic
profiles of BIBF 1120 and docetaxel and possible Pharmacokinetic (PK) interactions between
BIBF 1120 and docetaxel and to obtain preliminary information on anti-tumour activity.